The off-label use of dupilumab has proven to be an effective treatment option for severe chronic actinic dermatitis (CAD). We present the first case of CAD presenting with dupilumab-induced erythrodermic psoriasiform dermatitis. A modified, spaced dupilumab dosing regimen, combined with cyclosporine, successfully managed both conditions, offering a promising strategy for managing dupilumab adverse effects while maintaining control over chronic actinic dermatitis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583077 | PMC |
| http://dx.doi.org/10.1002/ccr3.9590 | DOI Listing |
Publication Analysis
Top Keywords
chronic actinic
12
actinic dermatitis
12
dupilumab-induced erythrodermic
8
erythrodermic psoriasiform
8
psoriasiform dermatitis
8
dermatitis
5
dermatitis chronic
4
dermatitis case
4
case report
4
report innovative
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!